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A b s t r a c t
Dual antiplatelet therapy (DAPT) has been the cornerstone of antithrombotic management for patients undergoing percu-
taneous coronary intervention (PCI). Despite low-quality evidence, triple antithrombotic therapy involving acetylsalicylic 
acid, clopidogrel, and warfarin or non-vitamin K antagonist oral anticoagulant (NOAC) has been recommended in patients 
with concomitant atrial fibrillation undergoing PCI, who require long-term oral anticoagulation, although such a strategy is 
associated with a substantially increased risk of bleeding compared with DAPT. NOAC combined with P2Y12 inhibitor alone 
appears to be safer and as effective as triple therapy with warfarin in patients with acute coronary syndromes based on the 
results of recent randomised trials on dabigatran and rivaroxaban. The present review summarises the current data on various 
combinations of antithrombotic agents in terms of their efficacy and safety.
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INTRODUCTION
Antithrombotic therapy, consisting of anticoagulant and 
antiplatelet agents, has become increasingly complex be-
cause of the advent of new medications, new indications, 
and competing clinical presentations. As a result, clinicians 
frequently encounter patients being treated with, or with ap-
parent indications for, multiple antithrombotic medications, 
and they are left to make difficult decisions about the type 
of the agent(s), duration of use, and the conditions under 
which one or more agents can be temporarily interrupted or 
permanently discontinued. 
Traditionally, dual antiplatelet therapy (DAPT) denotes 
the combination of acetylsalicylic acid (ASA) 75 to 100 mg 
qd plus an P2Y12 inhibitor (clopidogrel 75 mg qd, ticagrelor 
90 mg bid, or prasugrel 10 mg qd).
Triple antithrombotic therapy encompasses the use of 
an oral anticoagulant plus two antiplatelet agents, i.e. ASA 
75 to 100 mg qd plus an P2Y12 inhibitor, mostly clopidogrel 
75 mg qd.
WHEN SHOULD I USE DUAL  
ANTITHROMBOTIC THERAPY?
There are very limited circumstances within which there is 
moderate- or high-quality evidence to support combining an 
antiplatelet drug with an anticoagulant. Studies done many 
years ago show that the combination of warfarin and ASA was 
more effective than ASA alone in patients following an acute 
coronary event, as shown by a reduced rate of myocardial 
infarction (MI) or death, but at the cost of increased bleeding 
[1–4]. However, such combination therapy has been largely 
replaced by DAPT, particularly in the era of percutaneous 
coronary intervention (PCI).  
In patients with mechanical heart valves, there is mod-
erate-quality evidence indicating that the combination of 
warfarin plus ASA in selected patients is superior to warfarin 
alone, but two things are notable: the first is that the body of 
evidence is quite small, consisting of less than 1000 patients; 
and the second is that these data came from trials conducted 
more than two decades ago [5–7]. Contemporary mechanical 
valve prostheses are less thrombogenic, and it is likely that 
the quality of warfarin anticoagulation has improved since the 
completion of these trials. Current guidelines provide conflict-
ing recommendations about the use of the combination in 
patients with mechanical valves [8, 9]. Given the fact that the 
benefit of ASA added to vitamin K antagonists (VKAs) with 
contemporary target international normalised ratios (INRs) has 
been demonstrated predominantly in patients with atheroscle-
rotic vascular disease [10] and such a combination increases 
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the risk of major bleeding [11], VKA plus ASA should not be 
prescribed to all patients with prosthetic valves, according to 
the 2017 European Society of Cardiology (ESC) guidelines [8]. 
Such therapy should be initiated for specific indications, 
particularly in patients following thromboembolic episode 
despite an adequate INR [8]. Low-dose ASA (75–100 mg/day) 
may be added to VKA in such circumstances. In patients with 
prosthetic heart valves who are treated with the combina-
tion of an antiplatelet drug and a VKA a target INR in the 
lower part of the recommended target range and a time in 
the therapeutic range (TTR) > 65% to 70% are suggested by 
current ESC guidelines [8].
In some clinical settings there is moderate- or high-quality 
evidence that the combination of an oral anticoagulant and 
an antiplatelet agent is either ineffective or harmful [12–15]. 
In 2007 the Warfarin Antiplatelet Vascular Evaluation (WAVE) 
trial investigators showed that in patients with peripheral artery 
disease (PAD), combination therapy was not more effective 
than antiplatelet therapy alone and was associated with excess 
bleeding [14]. Stroke, MI, or death from cardiovascular causes 
occurred at a similar rate among patients on combination ther-
apy and those receiving antiplatelet therapy alone (relative risk 
[RR] 0.92, 95% confidence interval [CI] 0.73–1.16), whereas 
life-threatening bleeding was observed more frequently in the 
former group (4.0% vs. 1.2%, RR 3.41, 95% CI 1.84–6.35) 
[14]. On the other hand, in the randomised trial evaluating 
the efficacy and safety of the combination of antiplatelet and 
moderate-intensity anticoagulation therapy in 1209 patients 
with atrial fibrillation (AF) or mitral stenosis, the rate of vascular 
death, nonfatal stroke, or systemic embolism was lower in 
combined therapy with the cyclooxygenase inhibitor triflusal 
plus acenocoumarol than in the anticoagulant arm, whereas 
there were no differences between the anticoagulant and the 
combined therapy arms in the rate of severe bleeding [15].
In other situations, dual antithrombotic therapy may be 
used, but this has not been rigorously tested. Patients who 
have separate indications for anticoagulant and antiplatelet 
therapies, for example patients with AF who undergo coronary 
artery bypass grafting (CABG), or AF patients who develop 
acute coronary syndrome (ACS), with or without coronary 
stenting, may be considered for treatment with the combina-
tion of single or dual antiplatelet therapy and an anticoagulant.
In summary, there is moderate- or high-quality evidence 
for the use of dual antithrombotic therapy after ACS, although 
this is not widely used any more given the improvements in 
antiplatelet therapy, and in selected patients with mechanical 
heart valves. In the absence of evidence from randomised con-
trolled trials, combination therapy is empirically used in some 
other settings, where improved efficacy is desired and where 
a significant increase in the risk of bleeding is also deemed 
acceptable. As a result of the perception of enhanced efficacy, 
there are large numbers of patients receiving the combination 
of oral anticoagulants and single or dual antiplatelet therapy. 
WHEN AND FOR HOW LONG SHOULD TRIPLE 
ANTITHROMBOTIC THERAPY BE USED?
The available data suggest that triple therapy should be 
reserved for patients who have a firm indication for both 
DAPT and an anticoagulant. The most frequent indication is 
an ACS (usually treated with a coronary stent implantation) 
with the concomitant indication for oral anticoagulation. This 
is most common in patients with AF but also includes those 
with left ventricular thrombus, mechanical heart valves, or 
recent (within the preceding one to three months) venous 
thromboembolism. Triple antithrombotic therapy is associated 
with a very high risk of bleeding, and the current evidence 
from recent randomised trials convincingly indicates that it 
is no more effective than dual antithrombotic therapy in the 
majority of patients, as described below. 
If a patient presents with AF and undergoes coronary 
stenting in 2018, there are three approaches to ASA therapy: 
none, low dose, or higher dose. Moreover, there are several 
choices of duration of ASA use, three different choices for 
adenosine diphosphate (ADP) receptor antagonists, and mul-
tiple choices for the duration of an ADP receptor antagonist. 
In terms of anticoagulant agents, there are five agents ap-
proved for AF (warfarin, dabigatran, rivaroxaban, apixaban, 
and edoxaban) at different doses or intensities. There may be 
as many as three million “reasonable” combinations of these 
drugs within their approved dosage regimens.
There has been substantial research regarding antithrom-
botic therapy in patients with AF who have coronary stents 
[16, 17]. The antithrombotic management of patients with AF 
receiving warfarin, who undergo PCI with stent insertion, re-
quires clinicians to weigh the thromboembolic risk against the 
risk of bleeding. It has been demonstrated that combination 
antithrombotic therapy increases the risk of major bleeding, 
which in patients with ACS is associated with a fivefold in-
creased risk of death within 30 days [18]. Large studies driven 
by clinical endpoints have demonstrated that, in the acute 
setting, the combination of ASA plus ticlopidine is superior to 
ASA plus warfarin for prevention of stent thrombosis, which 
has led to recommendations for the routine use of DAPT post 
stenting [16, 17]. 
There is controversy about how long DAPT should be 
continued after coronary stenting. Guidelines recommend 
at least two to four weeks for a bare metal stent and three 
to six months for a drug eluting stent (DES). It is likely that 
newer generation DESs will require shorter durations of DAPT 
compared with older DESs.
Large randomised controlled trials have demonstrated 
that anticoagulation with warfarin is superior to no therapy, 
ASA, or DAPT for stroke prevention in patients with AF [19]. 
Meta-analyses of randomised controlled trials in patients with 
nonvalvular AF indicate that VKA therapy reduces the risk of 
stroke or systemic embolism by 64% compared with placebo 
and by 39% compared with ASA [20, 21].
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The Atrial Fibrillation Clopidogrel Trial With Irbesartan 
for Prevention of Vascular Events-Aspirin (ACTIVE-A) demon-
strated that in patients with AF unsuitable for VKA therapy, 
a combination of clopidogrel and ASA compared with ASA 
reduced stroke risk by 28% but increased major bleeding by 
57% (2.0% vs. 1.3% per year). During a median of 3.6 years 
of follow-up, the rate of major vascular events was lower 
in patients receiving DAPT compared with those receiving 
ASA (6.8% vs. 7.6% per year; RR 0.89, 95% CI 0.81–0.98). 
The difference was primarily due to a reduction in the rate 
of stroke [22]. The ACTIVE-W study showed that warfarin is 
superior to ASA plus clopidogrel in patients at high risk of 
stroke (3.93% vs. 5.60%; RR 1.44, 95% CI 1.18–1.76) [23]. 
Therefore, oral anticoagulants are strongly preferred as the 
agents to prevent stroke in patients with AF, and DAPT is 
recommended as the intervention to reduce the risk of acute 
failure of a coronary stent.
A meta-analysis of ten studies published from 2004 to 
2010 involving 1349 patients who received triple therapy in-
cluding warfarin in most cases, showed the incidence of major 
bleeding at 30 days to be 2.2% (95% CI 0.7%–3.7%) [24]. 
Despite the fact that these small studies analysed heterogene-
ous patient populations, employed different co-interventions, 
and used various definitions of major bleeding, they provided 
a useful estimate of bleeding risk associated with triple therapy. 
On the other hand, the one-year bleeding rate is much higher 
than that at 30 days and reaches 12% [25], which underscores 
the need to minimise the exposure to triple therapy.
Several randomised trials have compared triple therapy 
with dual therapy in AF patients undergoing stenting. The 
WOEST trial was an open-label, intention-to-treat, ran-
domised trial in which triple therapy was compared with 
dual therapy involving anticoagulant and clopidogrel (thus 
omitting ASA) [26]. Indications for warfarin in this study 
were AF (69%), prosthetic heart valve implantation (10%), 
and other conditions. Overall, 25% of patients were enrolled 
post ACS. At one-year follow-up, lower bleeding and mor-
tality rates were observed in patients receiving warfarin plus 
clopidogrel compared with those on triple therapy (hazard 
ratio [HR] 0.36, 95% CI 0.26–0.50, and HR 0.39, 95% CI 
0.16–0.93, respectively) with no significant differences in the 
rate of thrombotic events [26]. The triple therapy group had 
a cumulative incidence of major bleeding at 44% after one 
year, while in the dual therapy group this risk was much lower 
(Fig. 1). Major bleeding was found in similar proportions of 
patients in both arms when the Thrombolysis In Myocardial 
Infarction (TIMI) definition was used. When the Bleeding 
Academic Research Consortium (BARC) definition was ap-
plied, serious bleeding (BARC 3) occurred less frequently 
in the DAPT group than in the triple-therapy group (6.5% 
vs. 12.7%; HR 0.49, 95% CI 0.28–0.86) [26]. The limitations 
of the WOEST study included the predominance of elective 
PCI procedures, extension of triple therapy unnecessarily for 
up to one year, frequent femoral artery access, underuse of 
proton-pump inhibitors, and an underpowered study design 
that could not detect a significant difference in the risk of 
stent thrombosis between two antithrombotic regimens [26]. 
The Open-Label, Randomised, Controlled, Multicentre 
Study Exploring Two Treatment Strategies of Rivaroxaban and 
a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy 
in Subjects with Atrial Fibrillation Who Undergo Percutaneous 
Coronary Intervention (PIONEER-AF) study was published in 
2016 (Fig. 2A). In this study 2124 patients with nonvalvular 
AF, who had undergone PCI with stenting (~12% ST-segment 
Figure 1. Rates of bleeding and vascular events in patients treated with dual antithrombotic therapy and triple therapy based on 
the results of the WOEST study [26]; ASA — acetylsalicylic acid; MI — myocardial infarction; IST — intracoronary stent thrombosis
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elevation MI patients) were enrolled. Patients with a history 
of stroke were excluded. The PIONEER AF-PCI trial allocated 
patients to three different antithrombotic strategies, i.e. group 1: 
rivaroxaban, 15 mg qd (or 10 mg qd for individuals with 
creatinine clearance of 30 to 49 mL/min) plus low-dose ASA; 
group 2: rivaroxaban, 2.5 mg bid, plus ASA (75–100 mg 
qd), and clopidogrel, 75 mg qd (or prasugrel, 10 mg qd, 
or ticagrelor, 90 mg bid); and group 3: triple therapy with 
dose-adjusted VKA (target INR 2–3) instead of rivaroxaban 
[27]. Patients receiving warfarin (TTR 65%) plus DAPT had the 
highest risk of TIMI major or TIMI minor bleeding requiring 
medical attention (Fig. 2A). With the other two strategies there 
was a highly significant reduction in the rate of the primary 
outcome of significant bleeding (HR for group 1 vs. group 3: 
0.59, 95% CI 0.47–0.76, and HR for group 2 vs. group 3: 
0.63; 95% CI 0.50–0.80). No difference in major bleeding 
or transfusion was observed across groups. There was no 
difference in the rate of the primary composite endpoint of 
cardiovascular death, MI, or stroke between the three groups 
(Fig. 2B) [27]. The trial was underpowered especially when 
individual efficacy endpoints were analysed. Previous studies 
showed that rivaroxaban at a dose of 5 mg bid or 2.5 mg bid 
combined with DAPT increases the risk of major bleeding 
in patients with a recent ACS compared with placebo (2.1% 
vs. 0.6%, p < 0.001) and intracranial haemorrhage (0.6% 
vs. 0.2%, p = 0.009), including the risk of fatal bleeding 
during a mean follow-up of 13 months when the 5-mg bid 
rivaroxaban group was compared with the 2.5-mg bid group 
among patients with ACS (0.4% vs. 0.1%, p = 0.04) [28, 29]. 
The regimen of rivaroxaban at a dose of 15 mg daily has not 
been approved in ACS patients or subjects with AF and cre-
atinine clearance of 50 mL/min or more. Of note, up to 5% 
of patients were treated with ticagrelor in group 1–3 (5.2%, 
4.8%, and 3.0%, respectively), while 1.7% in group 1, 1.6% 
in group 2, and 0.7% in group 3 received prasugrel. The use 
of ticagrelor does not appear to increase the risk of bleeding 
as compared to strategies involving clopidogrel [27]. 
The prospective, randomised, open-label Randomised 
Evaluation of Dual Antithrombotic Therapy with Dabi-
gatran versus Triple Therapy with Warfarin in Patients with 
Nonvalvular Atrial Fibrillation Undergoing Percutaneous 
Coronary Intervention (REDUAL-PCI) trial published in August 
2017 compared the dual antithrombotic therapy regimen of 
dabigatran, 110 mg bid or 150 mg bid, plus clopidogrel or 
ticagrelor with a triple antithrombotic therapy of warfarin plus 
clopidogrel or ticagrelor plus low-dose ASA (Fig. 3) [30]. The 
incidence of major or clinically relevant non-major bleeding 
during a mean 14-month follow-up was significantly lower 
in the 110-mg dual-therapy group as compared with the 
triple-therapy group in which TTR was 64% (HR 0.52, 95% 
CI 0.42–0.63). The bleeding risk was also lower in the 150-mg 
dual-therapy group as compared with the triple-therapy group 
(HR 0.72, 95% CI 0.58–0.88; Fig. 3A, B). In this study ASA 
was used for one to three months based on practical recom-
mendations [31, 32]. The incidence of MI, stroke, systemic 
embolism, death, or unplanned revascularisation was similar 
in the two dual-therapy groups combined as compared with 
the triple-therapy group (HR 1.04, 95% CI 0.84–1.29), with 
no between-group difference in the rate of serious adverse 
events, as shown in Figure 3C and D [30]. Twelve per cent 
of patients in the RE-DUAL trial received ticagrelor, with 
no signal of unfavourable safety profile. This trial validated 
Figure 2. Efficacy and safety of rivaroxaban use in patients with nonvalvular atrial fibrillation without prior stroke, who require 
oral anticoagulation and have undergone percutaneous coronary intervention. Antithrombotic therapy with rivaroxaban (at 
a dose of 15 mg qd or 2.5 mg bid) combined with P2Y12 inhibitor alone or with low-dose acetylsalicylic acid (ASA), respectively, 
reduces the risk of clinically relevant bleeding (major or minor bleeding according to Thrombolysis In Myocardial Infarction criteria  
or bleeding requiring medical attention) compared with the triple therapy with warfarin and target international normalisation 
ratio 2–3 (A). The efficacy of rivaroxaban-based therapy during follow-up is similar to that of triple therapy (B). Based on the 
results of the PIONEER-AF trial [27]. Dual antiplatelet therapy (DAPT) denotes dual antiplatelet treatment, i.e. ASA combined  
with clopidogrel or other P2Y12 inhibitor, mainly ticagrelor
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the concept that a strategy of dual antithrombotic therapy, 
consisting of oral anticoagulant plus P2Y12 inhibitor at regular 
doses, is non-inferior to the triple therapy and could reduce 
the bleeding risk.
HOW LONG SHOULD WE TREAT PATIENTS  
UNDERGOING CORONARY STENTING?
The ISAR TRIPLE study published in 2015 was designed to 
examine whether shorter or longer duration of antithrombotic 
therapy was needed in patients undergoing coronary stenting 
[33]. This study compared a six-week clopidogrel and ASA 
treatment course after DES implantation with a six-month 
therapy group. Warfarin was used in this trial mainly for AF 
(84%). The DAPT was administered following PCI, including 
32% of patients with ACS. The cumulative incidence of the 
primary composite thrombotic endpoint (cardiac death, MI, 
stent thrombosis, or stroke) was similar in both groups over 
the nine months of follow-up after randomisation, although 
an early rise in the frequency of these outcomes was seen in 
the patients who received short duration therapy. There was 
no difference in stent thrombosis. Patients allocated to the 
six-month treatment strategy had a higher risk of bleeding, 
but this difference was marginally significant [33].
The ESC published guidelines on the management of AF 
in 2016, including recommendations for patients with AF, 
who have had elective PCI with stenting [34], which were 
supported by the guidelines on DAPT in coronary artery dis-
ease published in 2017 [35]. It is estimated that up to 15% 
of AF patients will require stenting during their lifetime [34]. 
The ESC guidelines primarily divided patients into groups of 
a low and a high risk of bleeding and then recommended 
treatment based on their predicted risk of thrombosis (Fig. 4). 
In both these groups they recommend triple therapy: oral an-
ticoagulant (dabigatran, rivaroxaban, apixaban, or warfarin) to-
gether with ASA 75 to 100 mg/day plus clopidogrel 75 mg/day. 
If the patient following elective PCI with stent implantation is 
categorised as low risk of bleeding, triple antithrombotic ther-
apy is followed by dual therapy with an oral anticoagulant and 
ASA or clopidogrel, and then after 12 months for indefinite 
duration with an oral anticoagulant alone. For patients at high 
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Figure 3. Efficacy and safety of dabigatran use (150 mg or 110 mg bid) in patients with nonvalvular atrial fibrillation who under- 
went percutaneous coronary intervention. Dual antithrombotic therapy with dabigatran, regardless of its daily dose, reduces the  
cumulative rate of major or non-major clinically relevant bleeding defined by the International Society on Thrombosis and Haemo-
-stasis, compared with the triple therapy with warfarin and target international normalisation ratio of 2–3 (A, B). The efficacy  
of dual dabigatran-based therapy in terms of serious thromboembolic events (a combined endpoint) during follow-up is similar 
to that for triple therapy (C, D). Based on the results of the RE-DUAL trial [30]
A B
C D
risk the therapeutic strategy is the same but instead of the dual 
therapy continuing from one to 12 months, the dual therapy 
continues from one to six months and after six months they 
recommend switching to an oral anticoagulant alone [34, 35]. 
Dual therapy with an anticoagulant combined with ASA or 
clopidogrel may be considered beyond one year in patients 
at very high risk of coronary events, including ≥ three stents 
implanted, diffuse multivessel disease particularly in dia-
betic patients, total stent length > 6 cm, and history of stent 
thrombosis on antiplatelet therapy [35]. The ESC guidelines 
state that therapy with any oral anticoagulant plus clopidogrel 
75 mg/day may be considered as an alternative to initial triple 
therapy in selected patients, including those at high risk of 
gastrointestinal bleeding [34]. 
The use of ticagrelor or prasugrel in triple therapy is not 
recommended [34, 35]. However, based on the results of the 
RE-DUAL-AF and PIONEER-AF trials, where a small subset of 
AF patients received ticagrelor [27, 30], this antiplatelet agent 
may be used if there is a clear need for its administration, 
particularly in patients who have experienced stent thrombosis 
while on dual therapy with ASA plus clopidogrel.
This is to be differentiated from patients who have ACS 
and AF, who are presumably higher-risk patients because they 
present with acute myocardial ischaemia, and who are at high 
risk of recurrent ischaemia. These patients are also divided 
into groups of low risk or high risk of bleeding. In the low-risk 
patients triple therapy should be continued for six months fol-
lowed by six months of dual therapy (oral anticoagulant plus 
ASA or clopidogrel) and then indefinite duration oral antico-
agulant monotherapy from one year after the ACS. Those with 
a high bleeding risk are allocated to one month of triple therapy 
followed by 11 months of dual therapy (oral anticoagulant plus 
ASA or clopidogrel) followed by oral anticoagulant therapy 
alone [32, 34, 36]. These recommendations highlight recent 
efforts to limit the duration of exposure to multiple antithrom-
botics as a mechanism to reduce the risk of avoidable bleeding. 
The 2017 ESC guidelines recommend that when an 
NOAC is used in combination with ASA and/or clopidogrel, 
the lowest approved dose effective for stroke prevention 
tested in AF trials should be considered, namely apixaban 
5 mg bid or apixaban 2.5 mg bid if ≥ two criteria are met 
from the following: age ≥ 80 years, body weight ≤ 60 kg, or 
serum creatinine level ≥ 1.5 mg/dL (133 µmol/L); dabigatran 
110 mg bid, rivaroxaban 20 mg qd, or rivaroxaban 15 mg qd 
if creatinine clearance is 30 to 49 mL/min (the lower rivaroxa-
ban dose is, however, suggested to reduce bleeding risk) [35].
Figure 4. The use of triple and dual antithrombotic therapies in patients undergoing percutaneous coronary intervention (PCI) 
based on the 2017 European Society of Cardiology guidelines [35]. A. Patients with high ischaemic risk, including those follo-
wing acute coronary syndromes treated with coronary stenting; B. Patients with high bleeding risk assessed using HAS-BLED or 
ABC scoring systems; two options are available, with or without four weeks on triple therapy. Patients receiving vitamin K anta-
gonist should achieve international normalisation ratio values between 2 and 2.5, while those receiving non-vitamin K antagonist 
oral anticoagulants should use anticoagulants at the lowest approved daily dose; ASA — acetylsalicylic acid
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Bleeding risk can be mitigated through other simple 
strategies including using the radial approach for angiography. 
The 2017 ESC guidelines strongly recommend that radial over 
femoral access should be used for coronary angiography and 
PCI if performed by an expert radial operator [35]. The radial 
approach is associated with lower rates of access site complica-
tions, including haematoma, pseudo-aneurysm, and bleeding 
at the access site, although time intervals from admission to 
balloon inflation are usually longer when the transradial access 
is used [37]. In a meta-analysis comprising 12 randomised 
controlled trials involving 5055 patients with MI treated by 
all regimens of anticoagulants, radial approach was associated 
with decreased risk of death and major bleeding [38].
Strategies that may further reduce the risk of bleeding 
in patients who receive triple therapy include the following:
1. Using the lowest proven effective dose of ASA to reduce 
the risk of gastrointestinal bleeding, i.e. based on the 
Antithrombotic Trialists’ Collaboration analyses [39], 75 to 
100 mg/day because such doses were no less effective 
than higher doses in secondary prevention of major 
cardiovascular events. 
2. Adding a proton pump inhibitor as prophylaxis against 
gastrointestinal bleeding in patients receiving DAPT or 
in those requiring the combination of antiplatelet and 
anticoagulant therapy. 
3. Avoiding nonsteroidal anti-inflammatory drugs to reduce 
the risk of gastrointestinal bleeding.
4. Ensuring optimal control of anticoagulation targeting an 
INR of 2 to 2.5 for patients receiving triple therapy, al-
though the effectiveness and safety of this approach have 
not been convincingly demonstrated. Evidence-based 
methods to improve control of VKA therapy that might 
be useful also in patients receiving triple therapy include 
specialist anticoagulation clinics, self-monitoring with 
a point-of-care device, and computerised dosing algo-
rithms [24, 40].
CONCLUSIONS
In summary, triple antithrombotic therapy, compared with 
dual antithrombotic therapy, is of unproven benefit in AF pa-
tients who have undergone stenting, and increases the risk of 
bleeding. During recent years, guidelines and expert opinions 
have significantly evolved in disfavour of triple therapy. They 
suggest that dual antithrombotic therapy with NOACs could be 
used in AF patients undergoing PCI with stenting, in particular 
those at high bleeding risk. Further experimental efforts are 
needed to seek new safe and effective therapeutic strategies 
in AF patients undergoing PCI, in whom it is extremely difficult 
to balance the prevention of stent thrombosis and stroke with 
the risk of major bleeding.
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